Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma

NCT02733809 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Sorafenib

Sponsor

King Saud University

Collaborators

[object Object]